EOM Prescribed drugs, a privately held, scientific-phase firm, introduced these days the appointment of enterprise veteran Wayne I. Danson, CPA, as Chief Economic Officer and Treasurer. Mr. Danson will be responsible for main the Firm’s fiscal operations including economical scheduling and investigation, funds marketplaces, trader relations, accounting, tax and treasury.
Mr. Danson has more than 35 many years of practical experience in economical leadership and management. He was most just lately President and Chief Government Officer of Danson Companions, LLC, a economic advisory and enterprise consulting organization, specializing in finance, mergers and acquisitions (M&A), enterprise system, interim CEO/CFO and turnaround consulting as well as tax companies, which he established in 1999.
Prior to that he was a Lover in big multinational accounting corporations and a previous Chief Govt Officer and Board Member of 1 of the premier reverse logistics organizations in the nation. He co-founded JDAP Money Advisors, LLC a private expenditure management company and established Encompass Group Affiliate marketers, Inc., a publicly traded logistics corporation that as President, CEO and Chairman of the Board, he grew the business enterprise to about $100 million in income. Mr. Danson also at this time serves as the Chairman of the Board of The Youngster Basis, a national charitable firm devoted to producing cures for all forms of children’s interstitial and diffused lung illnesses. Mr. Danson joins an accomplished executive staff with a deep legacy in numerous therapeutic places as nicely as organization results, like:
- Irach Taraporewala, Ph.D.: EOM Chief Executive Officer and Director, has numerous achievements in drug discovery, improvement and shipping and delivery, formulation, healthcare devices, radiopharmaceutical and DNA diagnostics, and regulatory affairs. His R&D contributions span several therapeutic regions, such as ophthalmology, cancer, irritation, immunology, endocrine, CNS, infectious disease, malaria and cachexia. Dr. Taraporewala also was the founder, CEO, President, and Board member of OHR Prescribed drugs, Inc. (NASDAQ-OHRP).
- Eli Goldberger: EOM’s Founder, Chairman and Chief Running Officer, a profitable entrepreneur, focusing on advancing innovations in prescription drugs, women’s wellness, and vitality.
- Shalom Z. Hirschman, M.D.: EOM Co-Founder, Chief Scientific Officer and Medical Director, served for over 30 a long time as the Director of Infectious Conditions and Vice Chairman of the Mount Sinai College of Drugs, was a founder of Touro College and the 1st to recognize HIV/AIDS. Dr. Hirschman also served as CEO, President, and Chief Scientific Officer of State-of-the-art Viral Research Corp.
“Wayne delivers a wealth of economical experience and government leadership to EOM as we get ready to secure more funding to even further commit in scientific trial progress for our lead compounds, EOM613 and EOM147, equally of which have presently been in Stage 2 medical trials and have shown enhanced pertinent medical actions and tolerability,” reported Dr. Taraporewala, EOM Chief Govt Officer and Director. “We are fortuitous to have another person of Wayne’s caliber be a part of our management staff and I am delighted to have him lead our financial strategy and attempts at this significant time for our rising organization.”
“I am excited to join the seasoned and achieved team at EOM as we embark on building our ground breaking therapeutic suite of products built to enhance the health and fitness and wellbeing of patients,” claimed Mr. Danson.
About EOM613
EOM613 is an investigational, to start with-in-course, dual-acting, broad-spectrum immunomodulator intended to offer both equally an anti-inflammatory outcome at the web site of cytokine and chemokine overactivity, and a professional-inflammatory result, when necessary. By re-establishing balance, EOM613 may rescue, maintenance, and restore an immune system that has been confronted by an invading antigen, pathogen, or virus. This twin-acting, broad-spectrum solution could overcome a critical limitation of standard immunomodulators. EOM613 has previously demonstrated medical enhancements in several ailment states, and immune-associated biomarkers and normal tolerability throughout five Phase 2 medical trials in patients with cachexia affiliated with AIDS and cancer, and in people with rheumatoid arthritis. EOM613 is effectively made from easily readily available supplies. Clinical trials are now getting prepared to review EOM613 to take care of clients with the most significant consequences of COVID-19 and for individuals with most cancers cachexia, a chemokine-linked physique-throwing away syndrome.
About EOM147
EOM147 is getting designed as a proprietary, newly reformulated squalamine-centered eye drop, containing a steroid-polyamine conjugate compound with broad-spectrum antimicrobial action and anti-angiogenic action. Extra clinical trials in India and Mexico are prepared to assess EOM147 in the therapy of several retinal disorders that can lead to blindness, like age-related macular degeneration (AMD) and diabetic retinopathies. The novel formulation signifies a prospective breakthrough due to the fact it does not require intraocular injection into the eye and, if permitted, would be the initial topically administered eye drop to deal with retinal conditions.
About EOM Pharmaceuticals
EOM Prescription drugs is a privately held, medical-phase pharmaceutical business with a pipeline of goods that have already proven scientific relevance in several Phase 2 medical trials. The Firm’s mission is to pursue ground breaking strategies with novel forms of compact molecule therapeutics to clear up the difficulties of some of present-day most urgent and unmet health-related demands. EOM’s pipeline is built on proprietary innovations made to rescue, maintenance, and restore wellness. These innovations involve the advancement of the to start with-and-only dual-acting, wide-spectrum immunomodulator EOM613, which has the opportunity to handle systemic disease owing to an intensive inflammatory immune reaction, together with COVID-19, influenza, and most cancers cachexia, and its sophisticated formulation of EOM147, the very first prospective topically administered eye drop to handle retinal health conditions. Numerous Period 2 trials suggest EOM613 and EOM147 have enhanced appropriate clinical actions and are very well tolerated.
For a lot more info about EOM Prescription drugs, please stop by www.eompharma.com.
Check out source version on businesswire.com: https://www.businesswire.com/information/household/20201217006039/en/
More Stories
Sales Build in November as Inventories Grow
A Two-Way Communication Tool for Teachers
My 50th birthday celebrations in Amsterdam